$13.21
3.26% today
Nasdaq, Aug 26, 10:00 pm CET
ISIN
US19207A1088
Symbol
COEP

Coeptis Therapeutics Stock price

$13.21
+1.21 10.08% 1M
+1.93 17.11% 6M
+7.71 140.18% YTD
+9.06 218.16% 1Y
-190.39 93.51% 3Y
-184.79 93.33% 5Y
-184.79 93.33% 10Y
-184.79 93.33% 20Y
Nasdaq, Closing price Tue, Aug 26 2025
-0.45 3.26%
ISIN
US19207A1088
Symbol
COEP
Industry

Key metrics

Basic
Market capitalization
$65.8m
Enterprise Value
$65.5m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
15.3
Financial Health
Equity Ratio
53.5%
Return on Equity
-493.0%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $6.0m
EBIT
- | $-12.4m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 129.4%
EBIT
- | 42.1%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
2.6%
Employees
6
Rev per Employee
$0.0
Show more

Is Coeptis Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Coeptis Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Coeptis Therapeutics forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Coeptis Therapeutics forecast:

Hold
50%
Sell
50%

Financial data from Coeptis Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
-
-
- Research and Development Expense 6.40 6.40
-
-
-20 -20
-
-
- Depreciation and Amortization 1 1
-
-
EBIT (Operating Income) EBIT -21 -21
67% 67%
-
Net Profit -21 -21
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about Coeptis Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Coeptis Therapeutics Stock News

Neutral
GlobeNewsWire
about one month ago
WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).
Neutral
GlobeNewsWire
2 months ago
WEXFORD, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the filing of a registration statement on Form S-4 with the Securities and Exchange Commission ("SEC") related to the Company's previously announced and proposed definitive merger agreement (t...
Neutral
GlobeNewsWire
3 months ago
WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences' proprietary Snap-Car ...
More Coeptis Therapeutics News

Company Profile

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company. It develops innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

Head office United States
CEO David Mehalick
Employees 6
Founded 2017
Website coeptistx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today